ORAMED PHARMACEUTICALS INC. ORMP

About ORAMED PHARMACEUTICALS INC. (ORMP): stock profile, AI score and financials

ORAMED PHARMACEUTICALS INC. (ORMP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ORMP at 44.5/100 on a composite quality score built from its SEC filings, placing it at rank #1,867 of 2,886 stocks — the bottom half of the AI-ranked universe. ORMP scores in the top quartile across profitability (100.0), balance sheet strength (99.8), institutional flow (86.3). Areas of concern include revenue scale (1.9) and free cash flow (3.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2026), ORAMED PHARMACEUTICALS INC. reports net income of $78.2M, free cash flow of $-202.0K. Top institutional holders of ORMP by reported 13-F value include MERCER GLOBAL ADVISORS, Aquamarine Financial (Cayman) Ltd, Gem Investment Advisors, based on the most recent SEC filings. ORMP trades on the Nasdaq exchange and files with the SEC under CIK 1176309. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORMP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ORAMED PHARMACEUTICALS INC. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1176309 →